Business Description
NeuBase Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US67778H2004
Compare
Compare
Traded in other countries / regions
NBSE.USAO7P.GermanyNBSE.Mexico IPO Date
2014-02-18Description
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.36 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.6 | |||||
| 3-Year FCF Growth Rate | 39.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.91 | |||||
| 9-Day RSI | 48.47 | |||||
| 14-Day RSI | 41.97 | |||||
| 6-1 Month Momentum % | 40.15 | |||||
| 12-1 Month Momentum % | -66.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.87 | |||||
| Quick Ratio | 2.87 | |||||
| Cash Ratio | 2.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -126.1 | |||||
| Shareholder Yield % | 40.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -90.04 | |||||
| ROA % | -56.88 | |||||
| ROIC % | -140.98 | |||||
| ROC (Joel Greenblatt) % | -202.16 | |||||
| ROCE % | -67.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.17 | |||||
| Price-to-Tangible-Book | 0.17 | |||||
| EV-to-EBIT | 0.41 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-FCF | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 0.4 | |||||
| Price-to-Net-Cash | 0.51 | |||||
| Earnings Yield (Greenblatt) % | 243.9 | |||||
| FCF Yield % | -940.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeuBase Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -7.197 | ||
| Beta | 0.31 | ||
| Volatility % | 103.15 | ||
| 14-Day RSI | 41.97 | ||
| 14-Day ATR (€) | 0.032688 | ||
| 20-Day SMA (€) | 0.35697 | ||
| 12-1 Month Momentum % | -66.73 | ||
| 52-Week Range (€) | 0.2902 - 3.68 | ||
| Shares Outstanding (Mil) | 3.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuBase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuBase Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeuBase Therapeutics Inc Frequently Asked Questions
What is NeuBase Therapeutics Inc(FRA:O7P)'s stock price today?
The current price of FRA:O7P is €0.38. The 52 week high of FRA:O7P is €3.68 and 52 week low is €0.29.
When is next earnings date of NeuBase Therapeutics Inc(FRA:O7P)?
The next earnings date of NeuBase Therapeutics Inc(FRA:O7P) is 2024-05-10 Est..
Does NeuBase Therapeutics Inc(FRA:O7P) pay dividends? If so, how much?
NeuBase Therapeutics Inc(FRA:O7P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers